Atypical hemolytic uremic syndrome with anti-factor H antibodies Advocacy Hub | UniteRare

At a Glance

Live from database

🔬

2Recruiting trials

Regulatory Watchboard

2 events

May 2024Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

Novartis Pharmaceuticals — PHASE3

TrialRECRUITING

Jan 2022Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Novartis Pharmaceuticals — PHASE3

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Atypical hemolytic uremic syndrome with anti-factor H antibodies.
Check the disease page for updates →

Clinical Trial Landscape

2 active trials

2Phase 3

2Total recruiting

Search clinical trials for Atypical hemolytic uremic syndrome with anti-factor H antibodies →

Recent News & Research

No recent news articles indexed yet for Atypical hemolytic uremic syndrome with anti-factor H antibodies.
Search PubMed for Atypical hemolytic uremic syndrome with anti-factor H antibodies →

Browse all Atypical hemolytic uremic syndrome with anti-factor H antibodies news →

Specialist Network

No specialists currently listed for Atypical hemolytic uremic syndrome with anti-factor H antibodies.

View all Atypical hemolytic uremic syndrome with anti-factor H antibodies specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰